Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

The purpose of this trial is to determine whether treatment with valsartan will have beneficial effect in early hypertrophic cardiomyopathy (HCM) by assessing many domains that reflect myocardial structure, function and biochemistry.

Stanford Investigator(s)


Primary Contact:
Euan Ashley, MD, PhD
(650) 498-4900